Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 11:6:19093.
doi: 10.1038/srep19093.

Pharmacologic Interventions in Preventing Ovarian Hyperstimulation Syndrome: A Systematic Review and Network Meta-Analysis

Affiliations

Pharmacologic Interventions in Preventing Ovarian Hyperstimulation Syndrome: A Systematic Review and Network Meta-Analysis

Jun-Liang Guo et al. Sci Rep. .

Abstract

Ovarian hyperstimulation syndrome (OHSS) is a severe iatrogenic complication of controlled ovarian stimulation. Randomised controlled trials (RCTs) have proven several pharmacologic interventions to be effective in OHSS prevention, but these trials have seldom compared multiple drugs. We identified randomised controlled trials (RCTs) through June 2015 by searching databases and compared 11 intervention strategies in preventing OHSS (primary outcome) and their influence on pregnancy rate (secondary outcome). A network meta-analysis was used to evaluate the relative effectiveness among treatments and to create a rank probability table. Thirty-one RCTs were identified, including 7181 participants. Five pharmacologic interventions were superior to placebo in decreasing OHSS incidence: aspirin [relative risk (RR) 0.07, 95% credible interval (CrI) 0.01-0.30, p < 0.05], intravenous (IV) calcium [RR 0.11, 95% CrI 0.02-0.54, p < 0.05], cabergoline [RR 0.17, 95% CrI 0.06-0.43, p < 0.05], metformin [RR 0.20, 95% CrI 0.07-0.59, p < 0.05] and IV hydroxyethyl starch (HES) [RR 0.26, 95% CrI 0.05-0.99, p < 0.05]. The rank probability demonstrated aspirin (Rank 1: 36%) and IV calcium (Rank 1: 35%) to be the most efficacious. Additionally, albumin might decrease the pregnancy rate when compared with placebo [RR 0.85, 95% CI 0.74-0.97, p < 0.05]. This conclusion provides a relative standard and objective reference for choosing an OHSS prophylactic agent.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flow diagram of the identification and selection of publications.
Figure 2
Figure 2
(a) Network figure of the evidence in the network meta-analysis for the primary outcome (OHSS incidence). Each red circle represents a pharmacological intervention. “c = n” represents the clinical trial number (including two 3-arm trials) between each comparator. Solid lines stand for the existence of direct evidence. Dotted lines represent no direct evidence. (b) Pooled relative risk and 95% credible interval (the numbers in parenthesis) of the primary outcome (OHSS incidence) based on the combination of direct and indirect evidence from the network meta-analysis. The longitudinal column interventions are compared with the transverse raw comparators. Bold numbers represents significant differences. (c) Rank probability figure for the interventions of network meta-analysis of the primary outcome (OHSS incidence) of ranks 1–5. A smaller rank number represents a better estimated effect. Each number (expressed in per cent) in this table demonstrates an estimated probability of an intervention to occupy a specific rank. Note. P/N = placebo or no treatment; HES = hydroxyethyl starch.
Figure 3
Figure 3. Forest plot of the direct pair-wise head-to-head comparisons between the interventions and their comparators for primary outcome (OHSS incidence).
“Experiment” in the plot represents intervention, and “control” represents comparator.

References

    1. Naredi N., Talwar P. & Sandeep K. VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status. Med J Armed Forces India 70, 58–63 (2014). - PMC - PubMed
    1. Garcia-Velasco J. A. & Pellicer A. New concepts in the understanding of the ovarian hyperstimulation syndrome. Curr Opin Obstet Gynecol 15, 251–6 (2003). - PubMed
    1. Binder H. et al. Update on ovarian hyperstimulation syndrome: Part 1–Incidence and pathogenesis. Int J Fertil Womens Med 52, 11–26 (2007). - PubMed
    1. Delvigne A. & Rozenberg S. A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients. Hum Reprod Update 8, 291–6 (2002). - PubMed
    1. Emperaire J. C. & Ruffie A. Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation syndrome. Hum Reprod 6, 506–10 (1991). - PubMed

Publication types

LinkOut - more resources